HomeORGANIZATION
ORGANIZATION

Japan Could Miss Out on Wave 1 of Drug Development, Re-Do and Do Right on PMP: PhRMA
(Jan.30.2018)

PhRMA Japan Executive Committee Chairman Patrik Jonsson
With the planned scale-down of the so-called price maintenance premium (PMP) to be carried out in April, Japan might not be able to maintain its position to be in the first wave of global clinical trials, the Pharmaceutical Research and Manufacturers of America (PhRMA) warned again on January 29 ...
(LOG IN FOR FULL STORY)